Prellis Biologics

Executive Summary

Prellis Biologics is a private biotechnology company based in San Francisco that leverages its proprietary EXIS™ platform to accelerate the discovery of fully human antibodies. The platform combines 3D bioprinting of lymph node organoids with artificial intelligence to recapitulate human immune responses in vitro, enabling rapid antibody generation against challenging targets such as GPCRs, ion channels, and multi-pass membrane proteins. By mimicking the natural immune system, Prellis aims to de-risk therapeutic development and reduce the time to candidate selection. The company’s technology addresses a critical bottleneck in biologics discovery, offering a high-throughput alternative to traditional immunization and phage display methods. Prellis is positioned to capture value in the growing therapeutic antibody market, with potential applications across oncology, autoimmune diseases, and infectious diseases. The company’s ongoing efforts include building strategic partnerships with pharmaceutical firms seeking novel antibodies against difficult targets, as well as advancing its internal pipeline. While Prellis remains in a relatively early stage, its innovative platform has the potential to disrupt antibody discovery and attract further investment. Key upcoming milestones include the closing of a Series B financing round and the publication of preclinical validation data that could validate the platform’s broad utility.

Upcoming Catalysts (preview)

• Q3 2026Series B financing round close75% success
• Q4 2026Partnership agreement with a major pharma for antibody discovery60% success
• Q4 2026Publication of preclinical validation data in a peer-reviewed journal85% success